[creation site internet] [logiciel creation site] [creation site web] [index]
[JMDThèque Technology]
[OSM Datasheet]
[OMH Datasheet]
[JMDThèque-New]
[JMDThèque-order-choix pays]
[JMDThèque Imaging]
[JMDThèque Imaging]
[Exe_Sum_Biomedical]
[Exe_Sum_Skin_Treatment]
[JMDThèque Imaging]
[Exe_Sum_Telecom]
[JMDThèque Telecom]
[Exe_Sum_Telecom2]
[JMDThèque Micro-Machining & Welding]
[JMDThèque Defense]
[JMDThèque Bio-Agronomy]
[Exe_Sum_Bioagronomy]
[JMDThèque Gaming]
[Exe_Sum_Gaming]
[UAV-DroneForSearchAndRescue]
[JMDThèque Investors Relations]
[Contact Us]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[]

OUR PARTNERS :

© JMDThèque - 2013

The development plan ends up to a demonstration of this new biomolecular analysis biotechnology in June 2015, through a scanner prototype realization (proof of concept). This prototype will allow first agreements with major financial and industrial investors for industrialisation and commercialization.

The business plan is based on the creation (in progress) of a JMDThèque subsidiary.

This subsidiary will receive an exclusive licence of JMDThèque and CEA technologies and their biomolecule analysis applications.

It will be inclined to develop the practice prototyping, then to start the industrial stage, either directly or in a limited partnership with a major industrialist.

The Market approach

The aimed target concerns laboratories and clinics, which have a semi-quantitative approach allowing to characterize the pathological and epidemiological risk (1500 euro per analysis) and a clinical diagnosis based on a quickly and reliably quantitative approach.
The whole scanner market was 175 M€ in 2005, with an annual growth rate of 21% since 2000.
The estimated market is 720 M€ in 2015, representing 8000 scanners 90k€ each.

JMDThèque seeks the following market share:

          - 2% in 2017, representing 160 scanners (115 k€ each)

          - 8% in 2020

          - 20% in 2025

JMDThèque offers attractive participation to Partners interested by the potential of development of this technology applied to Biomedical.

°          °
°

Memo: BreizhTech Company (who unfortunately ceased activity in july 2009) was established on May 2005 by Jean-Marc Desaulniers, Montreal Polytechnic graduated (Electrical Engineering- 1988) and Laval University (Biochemistry degree-1984). He has an international experience of 20 years in multimedia telecommunications, from R&D to Projects Direction. He held down the position of “Partnership Officer” for Alcatel mobile network division (North America) in his last job at Alcatel Lucent, and sales engineer. He was European Vice President of IMS Forum « Internet Multimédia Subsystem » in 2005-2006. His team consists of young engineers in France and Quebec in mechanics, optics, electronics and real-time embedded software. Several high-level personalities have joined him in 2007 in an « Advisory Board », helping him in strategic, marketing and financial terms. He has established partnerships with ebm papst (high precision motors), Thomson Multimedia (Futurimage Consortium), and a network of subcontractors for mechanical and optical realization. BreizhTech, Bretagne Entreprendre 2006 winner, has received support from OSEO Anvar from 2005 to 2007 (150 k€), and will receive assistance from Regional Council and Lannion-Trégor Agglomération (480 k€ in 2008-2009). JMDThèque Company (created in may 2007 by Jean-Marc Desaulniers) dedicated more specifically to R&D activities is now pursuing the R&D and Business Development effort initiated by BreizhTech, on every addressable market segments.

Industrial and commercial issues are related to the multiple biochips analyses applications : Medical Sector (genomics, diagnostics, drug screening, pharmacogenomics, medical forensic), Food Industry (contamination, classification), Environment (microbiological and/or chemical pollution), genetic identification.
In 15 years the biochips and reading systems (scanners) market, dominated by American companies, has explosed. It continues to grow exponentially.

The technological break process, based on CEA LIBS scanner process, consists to integrate JMDThèque technology to develop a new biochips scanner allowing a more direct, flexible, fast and cheaper reading than conventional technologies based on fluorescence measurements.
Moreover, this process breaking an actual lock technology allows an absolute DNA quantification, a better molecular mechanisms understanding and a new medical diagnosis approach.

The JMDThèque optomechatronic sub-system called « Digital Beam EngineTM » (DBE), benefits from latest real-time softwares and embedded electronics technological performances, allowing an accurate enslavement of optical discs and suitable powered lasers.
It builds up an electromagnetic multibeam scanning system, made with optomechatronic components initially developed by BreizhTech and JMDThèque.
It allows to superimpose several low-energy laser beams with an extreme accuracy and fastness on each biochip spot to generate micro-plasmas. The radiation of each irradiated spot is immediatly analyzed to characterize biomolecules.

°          °
°
CEA Life Sciences Department (Fontenay-aux-Roses, France) is a R&D leading actor in biotechnology. It has developed and patented a process allowing nucleic acids quantitative analysis (DNA, RNA on biochips), thanks to a phosphorus quantification scanner based on LIBS technology. This method alows diagnosis of a wide range of diseases and epidemics.

JMDThèque's technology allows, via moving optomechatronic components, to operate synchronous laser multibeam scanning for high-accuracy and high-energy projection on predetermined surfaces. BreizhTech technology has been awarded at the 36th  World Exhibition of Inventions at Geneva
 (Award of the French Research Ministry - 2008).

°          °
°
  

Biomedical : Biomolecules Quantitative Scanner
Technological alliance between CEA and an innovative small business company, JMDThèque